Human Metabolome Technologies, Inc. (6090.T)

JPY 679.0

(-1.88%)

EBITDA Summary of Human Metabolome Technologies, Inc.

  • Human Metabolome Technologies, Inc.'s latest annual EBITDA in 2023 was 306.48 Million JPY , down -2.78% from previous year.
  • Human Metabolome Technologies, Inc.'s latest quarterly EBITDA in 2023 FY was N/A , down -2.78% from previous quarter.
  • Human Metabolome Technologies, Inc. reported an annual EBITDA of 319.65 Million JPY in 2022, down -1.54% from previous year.
  • Human Metabolome Technologies, Inc. reported an annual EBITDA of 329.02 Million JPY in 2021, up 173.93% from previous year.
  • Human Metabolome Technologies, Inc. reported a quarterly EBITDA of N/A for 2023 FY, down -2.78% from previous quarter.
  • Human Metabolome Technologies, Inc. reported a quarterly EBITDA of -30.14 Million JPY for 2023 Q1, up 7.41% from previous quarter.

Annual EBITDA Chart of Human Metabolome Technologies, Inc. (2023 - 2019)

Historical Annual EBITDA of Human Metabolome Technologies, Inc. (2023 - 2019)

Year EBITDA EBITDA Growth
2023 306.48 Million JPY -2.78%
2022 319.65 Million JPY -1.54%
2021 329.02 Million JPY 173.93%
2020 108.33 Million JPY 244.3%
2019 23.84 Million JPY 0.0%

Peer EBITDA Comparison of Human Metabolome Technologies, Inc.

Name EBITDA EBITDA Difference
Shin Nippon Biomedical Laboratories, Ltd. 8.98 Billion JPY 96.587%
DNA Chip Research Inc. -217 Million JPY 241.237%
Cosmo Bio Company,Limited 669 Million JPY 54.188%
H.U. Group Holdings, Inc. 13.64 Billion JPY 97.754%
FALCO HOLDINGS Co., Ltd. 3.13 Billion JPY 90.214%
BML, Inc. 16.41 Billion JPY 98.133%
Precision System Science Co., Ltd. -661.75 Million JPY 146.314%